● Recruiting

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Condition: Pancreatic Cancer · Pancreatic Ductal Adenocarcinoma · PDAC · Sponsor: Dana-Farber Cancer Institute

PhaseEARLY_Phase 1

Planned participants5000

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersYes

About this study

The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.

This description comes directly from the study's public registry record.

Talk to the study team

Matthew Yurgelun, MD · 617-582-8673 · matthew_yurgelun@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Brigham and Women's Hospital	Boston, Massachusetts, United States	Not Yet Recruiting
Dana Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06122896